Analyst Ratings for Quest Diagnostics
Portfolio Pulse from Benzinga Insights
Quest Diagnostics (NYSE:DGX) has received indifferent ratings from four analysts in the last quarter. The average price target is $145.0, which is slightly above the current price of $141.92. This represents a 3.12% decrease from the previous average price target of $149.67.
June 29, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Quest Diagnostics has received indifferent ratings from analysts, with a slight potential upside based on the average price target.
The indifferent ratings from analysts suggest that there is no clear consensus on the stock's direction. However, the average price target is slightly above the current price, indicating a potential upside. This could have a neutral to slightly positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100